These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 2355000)

  • 1. Characterization of the functional defect in factor IX Alabama. Evidence for a conformational change due to high affinity calcium binding in the first epidermal growth factor domain.
    McCord DM; Monroe DM; Smith KJ; Roberts HR
    J Biol Chem; 1990 Jun; 265(18):10250-4. PubMed ID: 2355000
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ca2+ binding to the first epidermal growth factor-like domain of human blood coagulation factor IX promotes enzyme activity and factor VIII light chain binding.
    Lenting PJ; Christophe OD; Maat H; Rees DJ; Mertens K
    J Biol Chem; 1996 Oct; 271(41):25332-7. PubMed ID: 8810297
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Structural integrity of the gamma-carboxyglutamic acid domain of human blood coagulation factor IXa Is required for its binding to cofactor VIIIa.
    Larson PJ; Stanfield-Oakley SA; VanDusen WJ; Kasper CK; Smith KJ; Monroe DM; High KA
    J Biol Chem; 1996 Feb; 271(7):3869-76. PubMed ID: 8632006
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Interaction of factor IXa with factor VIIIa. Effects of protease domain Ca2+ binding site, proteolysis in the autolysis loop, phospholipid, and factor X.
    Mathur A; Zhong D; Sabharwal AK; Smith KJ; Bajaj SP
    J Biol Chem; 1997 Sep; 272(37):23418-26. PubMed ID: 9287357
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Baculovirus-mediated expression of the epidermal growth factor-like modules of human factor IX fused to the factor XIIIa transamidation site in fibronectin. Evidence for a direct interaction between the NH2-terminal epidermal growth factor-like module of factor IXa beta and factor X.
    Astermark J; Sottile J; Mosher DF; Stenflo J
    J Biol Chem; 1994 Feb; 269(5):3690-7. PubMed ID: 7906269
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The gamma-carboxyglutamic acid and epidermal growth factor-like modules of factor IXa beta. Effects on the serine protease module and factor X activation.
    Astermark J; Hogg PJ; Stenflo J
    J Biol Chem; 1994 Feb; 269(5):3682-9. PubMed ID: 8106413
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Blood coagulation factor IX residues Glu78 and Arg94 provide a link between both epidermal growth factor-like domains that is crucial in the interaction with factor VIII light chain.
    Christophe OD; Lenting PJ; Kolkman JA; Brownlee GG; Mertens K
    J Biol Chem; 1998 Jan; 273(1):222-7. PubMed ID: 9417068
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ligand requirements for Ca2+ binding to EGF-like domains.
    Mayhew M; Handford P; Baron M; Tse AG; Campbell ID; Brownlee GG
    Protein Eng; 1992 Sep; 5(6):489-94. PubMed ID: 1438159
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Factor IX Fukuoka. Substitution of ASN92 by His in the second epidermal growth factor-like domain results in defective interaction with factors VIIa/X.
    Nishimura H; Takeya H; Miyata T; Suehiro K; Okamura T; Niho Y; Iwanaga S
    J Biol Chem; 1993 Nov; 268(32):24041-6. PubMed ID: 8226948
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Coagulation factor IX residues G4-Q11 mediate its interaction with a shared factor IX/IXa binding site on activated platelets but not the assembly of the functional factor X activating complex.
    Ahmad SS; Wong MY; Rawala R; Jameson BA; Walsh PN
    Biochemistry; 1998 Feb; 37(6):1671-9. PubMed ID: 9484238
    [TBL] [Abstract][Full Text] [Related]  

  • 11. First epidermal growth factor-like domain of human blood coagulation factor IX is required for its activation by factor VIIa/tissue factor but not by factor XIa.
    Zhong D; Smith KJ; Birktoft JJ; Bajaj SP
    Proc Natl Acad Sci U S A; 1994 Apr; 91(9):3574-8. PubMed ID: 8170949
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antibody-probed conformational transitions in the protease domain of human factor IX upon calcium binding and zymogen activation: putative high-affinity Ca(2+)-binding site in the protease domain.
    Bajaj SP; Sabharwal AK; Gorka J; Birktoft JJ
    Proc Natl Acad Sci U S A; 1992 Jan; 89(1):152-6. PubMed ID: 1729682
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Structural determinants of the factor IX molecule mediating interaction with the endothelial cell binding site are distinct from those involved in phospholipid binding.
    Ryan J; Wolitzky B; Heimer E; Lambrose T; Felix A; Tam JP; Huang LH; Nawroth P; Wilner G; Kisiel W
    J Biol Chem; 1989 Dec; 264(34):20283-7. PubMed ID: 2555350
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Identification of functionally important residues of the epidermal growth factor-2 domain of factor IX by alanine-scanning mutagenesis. Residues Asn(89)-Gly(93) are critical for binding factor VIIIa.
    Chang YJ; Wu HL; Hamaguchi N; Hsu YC; Lin SW
    J Biol Chem; 2002 Jul; 277(28):25393-9. PubMed ID: 11960977
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of gamma-carboxyglutamic acid and epidermal growth factor-like modules of factor IX on factor X activation. Studies using proteolytic fragments of bovine factor IX.
    Astermark J; Hogg PJ; Björk I; Stenflo J
    J Biol Chem; 1992 Feb; 267(5):3249-56. PubMed ID: 1737781
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The epidermal growth factor-like domains of factor IX. Effect on blood clotting and endothelial cell binding of a fragment containing the epidermal growth factor-like domains linked to the gamma-carboxyglutamic acid region.
    Astermark J; Stenflo J
    J Biol Chem; 1991 Feb; 266(4):2438-43. PubMed ID: 1989995
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hemophilia B with mutations at glycine-48 of factor IX exhibited delayed activation by the factor VIIa-tissue factor complex.
    Wu PC; Hamaguchi N; Yu YS; Shen MC; Lin SW
    Thromb Haemost; 2000 Oct; 84(4):626-34. PubMed ID: 11057861
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparative platelet binding and kinetic studies with normal and variant factor IXa molecules.
    Ahmad SS; Rawala-Sheikh R; Monroe DM; Roberts HR; Walsh PN
    J Biol Chem; 1990 Dec; 265(34):20907-11. PubMed ID: 2249997
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Factor IX Bm Kiryu: a Val-313-to-Asp substitution in the catalytic domain results in loss of function due to a conformational change of the surface loop: evidence obtained by chimaeric modelling.
    Miyata T; Kuze K; Matsusue T; Komooka H; Kamiya K; Umeyama H; Matsui A; Kato H; Yoshioka A
    Br J Haematol; 1994 Sep; 88(1):156-65. PubMed ID: 7803238
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of lipid binding and kinetic properties of normal, variant, and gamma-carboxyglutamic acid modified human factor IX and factor IXa.
    Jones ME; Griffith MJ; Monroe DM; Roberts HR; Lentz BR
    Biochemistry; 1985 Dec; 24(27):8064-9. PubMed ID: 3879187
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.